Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
O’FARRILL-ROMANILLOS, Patricia María; LUNA-MUJICA, Ramón Fabricio; CONTRERAS-GARCIA, Carlos Eduardo y ANDA, Juan Carlos. Chronic kidney disease in adults with primary immunodeficiency diseases in treatment with intravenous immunoglobulin. Rev. alerg. Méx. [online]. 2020, vol.67, n.1, pp.25-33. Epub 16-Sep-2020. ISSN 2448-9190. https://doi.org/10.29262/ram.v67i1.707.
Background:
Intravenous immunoglobulin (IVIG) is the treatment of choice for humoral primary immunodeficiency diseases (PIDs). A third of the patients who receive intravenous immunoglobulin have adverse reactions, such as osmotic nephrosis.
Objective:
To assess the presence of kidney disease in adults with humoral PIDs, in treatment with intravenous immunoglobulin.
Methods:
A cross-sectional, descriptive, and observational study of patients who belong to the PID Clinic of the Specialties Hospital of the National Medical Center “Siglo XXI”, Mexico City, who receive treatment with intravenous immunoglobulin. A questionnaire with demographic information, 24h urine creatinine clearance, serum creatinine, urea, and BUN (Blood Urea Nitrogen) was applied.
Results:
35 patients were surveyed; 65.7 % were women; the average age was 34 years; 51.4 % of the patients presented kidney damage. Those with > 5 years of treatment with intravenous immunoglobulin presented chronic kidney disease (CKD) with more frequency (55.6 %) according to the KDOQI scale.
Conclusions:
Chronic kidney disease occurs in 51 % of adult patients with PID who have been treated with intravenous immunoglobulin for more than 5 years; which is why these patients require periodic evaluations of their kidney function, and the use of sugar-free immunoglobulin in order to reduce the risk.
Palabras llave : Common variable immunodeficiencies; Humoral immune response; Intravenous immunoglobulin; Chronic renal failure.